Download swiss med-tech hot-spot – opening up your business

Swiss Med-tech hotspot – Wednesday, 24th September 2014
SWISS MED-TECH HOT-SPOT –
OPENING UP YOUR BUSINESS
HORIZONS
OFFICIAL PROGRAM
Introduction
Many investors recognise Europe as an attractive and
transparent market where innovative companies wish to
expand and invest.
Switzerland is undoubtedly one of the best-known European
Med-tech hotspots where companies benefit from a central
European geographical location, an excellent infrastructure,
highly skilled human capital and an excellent R&D capacity.
Many Swiss Med-tech companies have their own R&D Units
and this creates a vibrant environment within the sector.
Med-tech product development requires precision, technical
expertise and complex knowledge, demanding interaction from
different fields and professionals such as engineers, doctors,
scientists and IT experts. Switzerland has an extremely highly
skilled workforce, capable of achieving such synergies among
these areas.
Switzerland has become a prominent centre for several
industry clusters, including Life Sciences, pharmaceuticals and
medical technology. A range of players are present, from
producers, suppliers and research institutes to third party
service providers. Investors will benefit from this vibrant
environment, allowing companies to prosper in terms of spinout as well as possible business synergies.
Reasons to consider Switzerland the leading Med-tech
hotspot and to attend this event:
 Switzerland hosts the most attractive companies in the field
such as Novartis Pharma, Synthes, Roche Diagnostics,
Sonova, Ypsomed and Straumann, Johnson & Johnson,
Zimmer, Medtronic, B. Braun and Stryker amongst many
others.
 Switzerland has a vast chain of suppliers in the Med-tech
industry, who are highly specialized.
 Total Med-tech turnover was estimated at CHF 12.5bn in
2011, which is equivalent to 2.1% of Swiss GDP. This
represents the highest share in the leading European medtech regions (UK: 0.4% of GDP and Germany: 0.8%).
 R&D is crucial for innovation. In Switzerland, Med-tech
manufacturers spend 13% of their turnover on R&D and
suppliers 8%. The Swiss Med-tech market spends
approximately CHF 1.4bn on R&D.
 The Swiss Med-tech market has the highest density of patent
applications within Europe.
 The Med-tech market is worth approximately CHF 7.2bn,
which represents 11% of Swiss healthcare expenses. The
industry experienced growth of 10% in 2010.
 In the vibrant environment of the Swiss Med-tech industry,
collaboration, quality and consistency are key success
factors.
 Switzerland has strong Life Science clusters with the
presence of a large number of global domestic companies
headquartered in its territory, as well as non-domestic
companies.
 The Life Science workforce represents a high percentage,
considering the total active population.
ConCep+
Think Tank & Strategy Consultant
Event Programme
th
Wednesday 24 September 2014
5.30pm Registration and Reception
6:00pm Welcome address by Ambassador Dominik Furgler
Presentation and Networking:
6.05pm
Why Switzerland is an attractive Market
Switzerland as an attractive Market
Ambassador of Switzerland to the United Kingdom,
HE Dr Dominik Furgler
6.20pm
Switzerland as the leading Med-tech hotspot in Europe
Dr Patrick Dümmler, Partner, Concept+
6.40pm
Biotechnology and Life Science in Switzerland
Dr Lutz-Peter Berg, Science & Technology Attaché, Embassy of
Switzerland
7.00pm
Testimonial
Mr Paul Cowan, Chairman & Chief Executive Officer
Quotient Limited
7.20pm
Break
7.30pm
Dinner
9.00pm Carriages
Contact
Ms Veronica Castel-Branco, Senior Investment Officer
Swiss Business Hub United Kingdom
DDI: +44 (0)20 7616 6050
Email [email protected]
RSVP by
th
Monday, 5 September 2014
Invitations are strictly personal and non-transferable